Qiagen (NYSE:QGEN) Upgraded at UBS Group

Key Points

• UBS Group upgraded Qiagen to a “hold” rating, joining a broader analyst consensus of “Hold” with an average price target of $43.51.
• Qiagen reported quarterly EPS of $0.62, exceeding the $0.60 consensus estimate, while revenue reached $535.04 million versus expectations of $527.50 million.
• The stock opened at $42.39, with a market capitalization of $8.74 billion; institutional investors and hedge funds own approximately 70% of shares.

Qiagen (NYSE:QGEN - Get Free Report) was upgraded by investment analysts at UBS Group to a "hold" rating in a note issued to investors on Wednesday, Zacks reports.

Several other research firms have also weighed in on QGEN. Weiss Ratings upgraded shares of Qiagen from a "sell (d+)" rating to a "hold (c-)" rating in a report on Monday, August 17th. Citigroup reissued a "neutral" rating and issued a $45.00 price target (up from $38.00) on shares of Qiagen in a report on Monday, August 10th. Stifel Nicolaus set a $40.00 price objective on shares of Qiagen in a research report on Friday, August 7th. Berenberg Bank set a $45.50 price objective on Qiagen and gave the stock a "hold" rating in a research note on Tuesday, July 14th. Finally, Barclays set a $40.00 target price on Qiagen and gave the stock an "equal weight" rating in a report on Friday, August 7th. One equities research analyst has rated the stock with a Strong Buy rating, four have given a Buy rating and nine have given a Hold rating to the company's stock. Based on data from MarketBeat, the stock currently has an average rating of "Hold" and an average price target of $43.51.

Qiagen Stock Performance

QGEN stock opened at $42.39 on Wednesday. Qiagen has a twelve month low of $32.53 and a twelve month high of $57.81. The business's fifty day moving average is $42.20 and its 200-day moving average is $40.18. The company has a quick ratio of 2.31, a current ratio of 2.85 and a debt-to-equity ratio of 0.48. The company has a market cap of $8.74 billion, a P/E ratio of 21.72, a price-to-earnings-growth ratio of 4.20 and a beta of 0.63.

Qiagen (NYSE:QGEN - Get Free Report) last posted its earnings results on Wednesday, August 5th. The company reported $0.62 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.60 by $0.02. Qiagen had a return on equity of 14.47% and a net margin of 19.49%.The company had revenue of $535.04 million during the quarter, compared to analyst estimates of $527.50 million. During the same period in the previous year, the company earned $0.60 EPS. The company's revenue for the quarter was up .2% compared to the same quarter last year. Qiagen has set its FY 2026 guidance at 2.430- EPS. Equities research analysts forecast that Qiagen will post 2.43 EPS for the current year.

Hedge Funds Weigh In On Qiagen

A number of institutional investors and hedge funds have recently added to or reduced their stakes in QGEN. Price T Rowe Associates Inc. MD lifted its holdings in shares of Qiagen by 12.1% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 8,429,424 shares of the company's stock valued at $379,072,000 after purchasing an additional 906,589 shares in the last quarter. Deutsche Bank AG increased its position in shares of Qiagen by 9.7% in the fourth quarter. Deutsche Bank AG now owns 7,907,801 shares of the company's stock valued at $355,614,000 after acquiring an additional 697,342 shares during the last quarter. Amundi increased its position in shares of Qiagen by 12.4% in the first quarter. Amundi now owns 4,757,681 shares of the company's stock valued at $190,498,000 after acquiring an additional 524,959 shares during the last quarter. Boston Partners bought a new stake in Qiagen during the third quarter worth about $179,450,000. Finally, Norges Bank bought a new stake in Qiagen during the fourth quarter worth about $166,500,000. 70.00% of the stock is owned by institutional investors and hedge funds.

About Qiagen

QIAGEN N.V. is a global provider of sample preparation, molecular testing and bioinformatics solutions used in life sciences research, molecular diagnostics and applied testing. The company develops technologies that help customers isolate and analyze DNA, RNA and other biological materials from blood, tissue and other samples.

Its offerings include laboratory instruments, consumables, assay kits and software. Key product areas include automated sample-processing systems, polymerase chain reaction (PCR) and digital PCR solutions, next-generation sequencing workflows, bioinformatics tools, and diagnostic tests such as QuantiFERON for tuberculosis testing and QIAstat-Dx for syndromic testing.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.